These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38334320)

  • 21. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
    Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
    JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
    Joshi S; Spargo A; Hoyt M; Panni T; Viktrup L; Kim G; Hasan A; Liu YY; Zakharyan A
    Headache; 2024; 64(7):796-809. PubMed ID: 38898657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Foster SA; Hoyt M; Ye W; Mason O; Ford JH
    Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
    Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
    Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study.
    Viudez-Martínez A; Pascual-Carrasco A; Beltrán-Blasco I; Hernandez-Lorido R; F Ruiz de Apodaca R
    J Clin Pharm Ther; 2022 Jun; 47(6):814-823. PubMed ID: 35212025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain.
    Irimia P; Santos-Lasaosa S; García Bujalance L; Ramos Pinazo L; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):285-297. PubMed ID: 32484365
    [No Abstract]   [Full Text] [Related]  

  • 34. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
    Moskatel LS; Graber-Naidich A; He Z; Zhang N
    Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M; Tullo V; Didier HA; Bussone G
    Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
    Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
    J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
    [No Abstract]   [Full Text] [Related]  

  • 37. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
    Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.
    Reuter U; Lucas C; Dolezil D; Hand AL; Port MD; Nichols RM; Stroud C; Tockhorn-Heidenreich A; Detke HC
    Adv Ther; 2021 Nov; 38(11):5465-5483. PubMed ID: 34542830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
    Detke HC; Millen BA; Zhang Q; Samaan K; Ailani J; Dodick DW; Aurora SK
    Headache; 2020 Feb; 60(2):348-359. PubMed ID: 31710104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.